Oliver von Richter

5.7k total citations · 2 hit papers
66 papers, 4.6k citations indexed

About

Oliver von Richter is a scholar working on Oncology, Pediatrics, Perinatology and Child Health and Pharmacology. According to data from OpenAlex, Oliver von Richter has authored 66 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 23 papers in Pediatrics, Perinatology and Child Health and 17 papers in Pharmacology. Recurrent topics in Oliver von Richter's work include Pharmacogenetics and Drug Metabolism (17 papers), Drug Transport and Resistance Mechanisms (16 papers) and Biosimilars and Bioanalytical Methods (16 papers). Oliver von Richter is often cited by papers focused on Pharmacogenetics and Drug Metabolism (17 papers), Drug Transport and Resistance Mechanisms (16 papers) and Biosimilars and Bioanalytical Methods (16 papers). Oliver von Richter collaborates with scholars based in Germany, United States and Japan. Oliver von Richter's co-authors include Michel Eichelbaum, Oliver Burk, Andreas Johne, Ulrich Brinkmann, J. Brockmöller, Thomas Gerloff, Ivar Roots, Sven Hoffmeyer, Ingolf Cascorbi and J Zundler and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Oliver von Richter

64 papers receiving 4.4k citations

Hit Papers

Functional polymorphisms of the human multidrug-resistanc... 1999 2026 2008 2017 2000 1999 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
    2000 2.0k citations Oliver von Richter, Andreas Johne et al. profile →
  2. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
    1999 734 citations Bernd Greiner, Michel Eichelbaum et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Oliver von Richter Germany 25 2.9k 1.8k 1.5k 973 492 66 4.6k
Andreas Johne Germany 23 2.4k 0.8× 1.5k 0.9× 1.1k 0.7× 706 0.7× 423 0.9× 85 4.2k
Kazuto Yasuda United States 30 2.7k 0.9× 1.4k 0.8× 2.6k 1.7× 1.0k 1.0× 518 1.1× 59 5.4k
Ichiro Ieiri Japan 45 3.3k 1.1× 1.9k 1.1× 2.1k 1.4× 1.2k 1.3× 643 1.3× 176 6.4k
Thomas Gerloff Germany 23 3.2k 1.1× 1.8k 1.0× 1.0k 0.7× 712 0.7× 461 0.9× 31 4.3k
Xiaoyan Chu United States 40 3.2k 1.1× 1.8k 1.0× 1.7k 1.1× 1.2k 1.2× 460 0.9× 90 5.0k
Reinhold Kerb Germany 42 3.3k 1.2× 1.8k 1.0× 1.6k 1.0× 1.8k 1.8× 460 0.9× 69 6.7k
Katsuhiko Okumura Japan 39 2.3k 0.8× 1.3k 0.7× 874 0.6× 1.4k 1.5× 603 1.2× 179 5.2k
Oliver Burk Germany 35 4.5k 1.6× 2.4k 1.3× 3.4k 2.3× 1.9k 2.0× 694 1.4× 68 8.0k
Brenda F. Leake United States 31 4.6k 1.6× 2.5k 1.4× 2.1k 1.4× 1.0k 1.1× 1.2k 2.5× 45 6.7k
Rommel G. Tirona Canada 39 3.1k 1.1× 1.4k 0.8× 2.0k 1.3× 1.1k 1.1× 489 1.0× 99 5.7k

Countries citing papers authored by Oliver von Richter

Since Specialization
Citations

This map shows the geographic impact of Oliver von Richter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver von Richter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver von Richter more than expected).

Fields of papers citing papers by Oliver von Richter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver von Richter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver von Richter. The network helps show where Oliver von Richter may publish in the future.

Co-authorship network of co-authors of Oliver von Richter

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver von Richter. A scholar is included among the top collaborators of Oliver von Richter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver von Richter. Oliver von Richter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gaylis, Norman, et al.. (2024). ‘Totality of Evidence’ Approach in the Development of GP2017, an Approved Adalimumab Biosimilar. Advances in Therapy. 41(5). 1795–1814. 2 indexed citations
2.
Chamberlain, Paul, Bernhard Hemmer, Hendrik Wessels, et al.. (2024). Comparative immunogenicity assessment of biosimilar natalizumab to its reference medicine: a matching immunogenicity profile. Frontiers in Immunology. 15. 1414304–1414304.
3.
4.
5.
6.
Richter, Oliver von, et al.. (2016). Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients. British Journal of Clinical Pharmacology. 82(6). 1498–1508. 22 indexed citations
7.
Macarulla, Teresa, Andrés Cervantes, Josep Tabernero, et al.. (2015). Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer. British Journal of Cancer. 112(12). 1874–1881. 30 indexed citations
8.
Verslype, Chris, Pascal Hammel, Manuel Hidalgo, et al.. (2013). Pimasertib plus gemcitabine in metastatic pancreatic adenocarcinoma: Results of a safety run-in part of a phase II trial.. Journal of Clinical Oncology. 31(15_suppl). 4041–4041. 5 indexed citations
9.
Glavinas, Hristos, Oliver von Richter, Kinga Vojnits, et al.. (2011). Calcein assay: a high-throughput method to assess P-gp inhibition. Xenobiotica. 41(8). 712–719. 30 indexed citations
10.
Nassr, Nassr, Rolf Herzog, Oliver von Richter, et al.. (2009). Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N‐oxide in healthy subjects. British Journal of Clinical Pharmacology. 68(4). 580–587. 34 indexed citations
11.
Lahu, Gëzim, Oliver von Richter, Róbert Hermann, et al.. (2008). Effect of Single and Repeated Doses of Ketoconazole on the Pharmacokinetics of Roflumilast and Roflumilast N‐Oxide. The Journal of Clinical Pharmacology. 48(11). 1339–1349. 30 indexed citations
12.
Glavinas, Hristos, Emese Kis, Ákos Pál, et al.. (2007). ABCG2 (Breast Cancer Resistance Protein/Mitoxantrone Resistance-Associated Protein) ATPase Assay: A Useful Tool to Detect Drug-Transporter Interactions. Drug Metabolism and Disposition. 35(9). 1533–1542. 56 indexed citations
13.
Richter, Oliver von, et al.. (2007). Effect of Fluvoxamine on the Pharmacokinetics of Roflumilast and??Roflumilast??N-Oxide. Clinical Pharmacokinetics. 46(7). 613–622. 29 indexed citations
14.
Hermann, Róbert, Gëzim Lahu, Nassr Nassr, et al.. (2006). Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clinical Pharmacology & Therapeutics. 79(4). 339–349. 94 indexed citations
15.
Richter, Oliver von, Cristina Rodríguez‐Antona, Anna Testa, et al.. (2004). Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6). Pharmacogenetics. 14(6). 369–379. 26 indexed citations
16.
Richter, Oliver von, Martin F. Fromm, Tanja Richter, et al.. (2003). Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 13(9). 565–575. 106 indexed citations
17.
Pitarque, Marià, et al.. (2001). Identification of a Single Nucleotide Polymorphism in the TATA Box of the CYP2A6 Gene: Impairment of Its Promoter Activity. Biochemical and Biophysical Research Communications. 284(2). 455–460. 128 indexed citations
18.
Schmolling, J., et al.. (2000). Digoxin, Flecainide, and Amiodarone Transfer Across the Placenta and the Effects of an Elevated Umbilical Venous Pressure on the Transfer Rate. Therapeutic Drug Monitoring. 22(5). 582–588. 12 indexed citations
19.
Greiner, Bernd, Oliver von Richter, Taher Omari, et al.. (1999). Shedded enterocytes as an ex vivo probe for gut wall metabolism. Clinical Pharmacology & Therapeutics. 65(2). 127–127. 1 indexed citations
20.
Richter, Oliver von, et al.. (1979). [Effects on platelet functions].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 97(7). 279–83. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andreas Johne Breakdown of academic impact, for papers by Kazuto Yasuda Breakdown of academic impact, for papers by Ichiro Ieiri Breakdown of academic impact, for papers by Thomas Gerloff Breakdown of academic impact, for papers by Xiaoyan Chu Breakdown of academic impact, for papers by Reinhold Kerb Breakdown of academic impact, for papers by Katsuhiko Okumura Breakdown of academic impact, for papers by Oliver Burk Breakdown of academic impact, for papers by Brenda F. Leake Breakdown of academic impact, for papers by Rommel G. Tirona
Rankless by CCL
2026